Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COTI 2

Drug Profile

COTI 2

Alternative Names: COTI-2

Latest Information Update: 13 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Critical Outcome Technologies
  • Developer Cotinga Pharmaceuticals; Northwestern University; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cyclin-dependent kinase modulators; Iron chelating agents; Methylenetetrahydrofolate reductase modulators; P53 gene modulators; Protein kinase inhibitors; Proto oncogene protein c-akt inhibitors; Thymidylate synthase modulators; Tubulin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Cancer
  • Phase I Cervical cancer; Endometrial cancer; Fallopian tube cancer; Head and neck cancer; Ovarian cancer; Peritoneal cancer
  • Preclinical Acute myeloid leukaemia; Li-Fraumeni syndrome
  • No development reported Colorectal cancer

Most Recent Events

  • 05 Nov 2018 Cotinga Pharmaceuticals and St Vincents University Hospital agree to co-develop COTI 2 for Breast cancer
  • 05 Nov 2018 Cotinga Pharmaceuticals and St Vincents university Hospital plans a phase I trial for Breast cancer (Combination therapy, Second-line therapy or greater, Metastatic disease)
  • 29 Aug 2018 Cotinga Pharmaceuticals plans a p53 basket trial in Solid tumours including breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top